Non-Uterine Leiomyosarcoma
Curated, nationally-relevant updates on maintenance therapy, combination immunotherapy/chemotherapy studies, and surgical outcomes in advanced soft tissue sarcoma with emphasis on leiomyosarcoma.
Sarcoma NGS Updates (ASCO 2025)
Next-Generation Sequencing, Targeted & Cellular Therapies
Neal Chawla, MD — ASCO 2025
Key updates on NGS adoption, NTRK fusion treatments, MAGE-A4 therapy for synovial sarcoma, ivosidenib for chondrosarcoma, B7H3 targeted therapies, and multimodal immunotherapy approaches.
Maintenance After First-Line Treatment
Advanced Soft Tissue Sarcoma
Evidence and perspectives on maintenance strategies following initial therapy
Peer-Reviewed Overview
Explore maintenance options and considerations for advanced STS after first-line therapy.
Maintenance Review (PubMed)
Review of 8 randomized trials: PFS gains with trabectedin (post doxorubicin/trabectedin) in LMS and anlotinib (post epirubicin/anlotinib) in STS; switch maintenance with regorafenib improved PFS in non-adipocytic STS; OS benefit seen with doxorubicin/trabectedin in LMS.
PubMed — AbstractSurgical Outcomes
IVC Resection & Graft Replacement
Single-center experience over three decades
Evaluating safety, durability, and local control following inferior vena cava resection with graft replacement for malignant disease. Reported as safe and durable with excellent local control, offering potential long-term survival in select patients.
Read the PubMed AbstractDrug Therapy Chart
Featured Sarcoma Drug Therapy Chart
Visual summary from ScienceDirect
Phase 2 TNT Study
Talimogene Laherparepvec (TVEC), Nivolumab & Trabectedin
Combination oncolytic immunotherapy and chemotherapy in advanced sarcomas
ASCO Abstract
Conference abstract overview of the TNT study
J Clin Oncol · e23560Full Text (PMC)
Open-access paper detailing eligibility, regimen, and outcomes
Frontiers in OncologyClinicalTrials.gov
Trial registry with protocol info and status updates
NCT03886311